Midodrine and Albumin in Patients With Refractory Ascites
Status:
Not yet recruiting
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
Refractory ascites is seen in 5-10% of patients with cirrhosis.Decompensated cirrhosis with
refractory ascites has a mortality rate of around 40% in a year and a median survival of 6
months.Portal hypertension and splanchnic vasodilation are major factors in the development
of ascites.The treatment of refractory ascites involves salt restriction, diuretics, large
volume paracentesis (LVP), transjugular Intrahepatic Portosystemic shunt (TIPS) and Liver
Transplantation (LT). Currently the only curative treatment is LT. However, LT is limited due
to organ shortage and high cost.
Long-term human albumin (HA) administration in patients with uncomplicated and refractory
ascites, has shown to improve survival or delay the complications of cirrhosis. Midodrine, an
oral α1- adrenergic agonist has been used in refractory ascites with variable results.
However, there is no study on the use of long term Midodrine and HA in patients with
refractory ascites. Therefore, we plan to study the effect of long term midodrine and HA in
patients with refractory ascites.
Phase:
Phase 3
Details
Lead Sponsor:
Postgraduate Institute of Medical Education and Research